Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julio Rosenstock

Showing results (1-10 of 340) with videos related to

Pageof 34
Sort By:
The American Journal of Medicine|March 12, 2004
Basal insulin supplementation in type 2 diabetes; refining the tacticsJulio Rosenstock
Diabetes Care|October 21, 2021
Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518Julio Rosenstock
Postgraduate Medicine|August 12, 2009
Exploring new frontiers in insulin therapy: lowering A1c to the max. IntroductionJulio Rosenstock
Diabetes, Obesity & Metabolism|March 15, 2008
Management of prediabetes: setting the stageJulio Rosenstock
Expert Review of Endocrinology & Metabolism|February 21, 2019
Clinical overview of saxagliptin for Type 2 diabetes managementJulio Rosenstock
Postgraduate Medicine|August 12, 2009
Redefining insulin therapy in type 2 diabetes mellitusJulio Rosenstock
Diabetes Care|July 27, 2016
Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638-1642Julio Rosenstock, Ele Ferrannini
Diabetes Care|February 20, 2021
Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?Ele Ferrannini, Julio Rosenstock
Expert Opinion on Pharmacotherapy|December 19, 2003
Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetesJulio Rosenstock, David Owens
Diabetes Care|October 30, 2007
Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!Julio Rosenstock, Vivian Fonseca
Pageof 34

Showing results (1-10 of 340) with videos related to

Sort By:
Pageof 34
The American Journal of Medicine|March 12, 2004
Basal insulin supplementation in type 2 diabetes; refining the tacticsJulio Rosenstock
Diabetes Care|October 21, 2021
Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518Julio Rosenstock
Postgraduate Medicine|August 12, 2009
Exploring new frontiers in insulin therapy: lowering A1c to the max. IntroductionJulio Rosenstock
Diabetes, Obesity & Metabolism|March 15, 2008
Management of prediabetes: setting the stageJulio Rosenstock
Expert Review of Endocrinology & Metabolism|February 21, 2019
Clinical overview of saxagliptin for Type 2 diabetes managementJulio Rosenstock
Postgraduate Medicine|August 12, 2009
Redefining insulin therapy in type 2 diabetes mellitusJulio Rosenstock
Diabetes Care|July 27, 2016
Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638-1642Julio Rosenstock, Ele Ferrannini
Diabetes Care|February 20, 2021
Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?Ele Ferrannini, Julio Rosenstock
Expert Opinion on Pharmacotherapy|December 19, 2003
Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetesJulio Rosenstock, David Owens
Diabetes Care|October 30, 2007
Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!Julio Rosenstock, Vivian Fonseca
Pageof 34